Clinical Significance of Some Biomarkers in the Detection of Kidney and Bladder Cancers
Keywords:
RCC, Bladder cancer, C7, CK7, CD117
Abstract
Background: Screening for biomarkers is the process of finding proteins, genes, and other components (also known as tumor markers or biomarkers) that may provide details about malignancy. Each person's cancer has a particular pattern of biomarkers. Some biomarkers influence how specific cancers develop. The aim of this study was to use biomarkers (C7, CK7. CD117) in the early diagnosis of cancer of the bladder and renal cancer.
Methods: A case-control study with 92 participants, 31 individuals in good health as the control group and 61 patients that correspond to the inclusion standards with an age range from (13 to 92) years, Kits were used to measure CLDN7, CK7. CD117 while Enzyme-Linked Immunosorbent Assay (ELISA).
Results: The current study showed significant differences (p< 0.05) in the Age with significant decrease of C7, CK7 and CD117 also showed no significant differences (p 0.057) in the BMI of Renal groups when compared to the case control. Additionally results showed significant differences (p< 0.05) in the Age (61.9) with significant decrease of C7, CK7 and CD117 showed significant increase, also showed no significant difference in BMI (P> 0.285) of Bladder groups when compared to the case control
Conclusion: The results of the current study demonstrated that the biomarkers C7, CK7, and CD117 can be utilized to diagnose renal cancer due to they all had decreasing concentrations, but only C7 and CK7 have decreasing concentrations in bladder cancer counter to (CD117) concentration is rising.
References
1. E. Laconi, F. Marongiu, and J. DeGregori, “Cancer as a disease of old age: changing mutational and microenvironmental landscapes,” Br. J. Cancer, vol. 122, no. 7, pp. 943–952, 2020, doi: 10.1038/s41416-019-0721-1.
2. H. Moch et al., “The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours,” Eur. Urol., vol. 82, no. 5, pp. 458–468, 2022, doi: 10.1016/j.eururo.2022.06.016.
3. V. K. Sarhadi and G. Armengol, “Molecular Biomarkers in Cancer,” Biomolecules, vol. 12, no. 8, pp. 1–39, 2022, doi: 10.3390/biom12081021.
4. I. Lorencin, N. Anđelić, J. Španjol, and Z. Car, “Using multi-layer perceptron with Laplacian edge detector for bladder cancer diagnosis,” Artif. Intell. Med., vol. 102, no. May 2019, 2020, doi: 10.1016/j.artmed.2019.101746.
5. K. L. Ng, “The Etiology of Renal Cell Carcinoma and Upper Tract Urothelial Carcinoma,” Urol. Cancers, pp. 61–69, 2022, doi: 10.36255/exon-publications-urologic-cancers-etiology-renal-cell-carcinoma.
6. H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
7. M. I. Tafwid, A. Rizky, and H. Pratama, “Association between patient with muscle-invasive bladder cancer with the incidence of urinary tract infection in Karawang Regional Hospital : a single center study,” vol. 11, no. 3, pp. 1494–1497, 2022, doi: 10.15562/bmj.v11i3.3823.
8. O. Bratu et al., “Renal tumor biomarkers (Review),” Exp. Ther. Med., vol. 22, no. 5, pp. 1–7, Sep. 2021, doi: 10.3892/etm.2021.10732.
9. A. Cinque, R. Vago, and F. Trevisani, “Circulating rna in kidney cancer: What we know and what we still suppose,” Genes (Basel)., vol. 12, no. 6, pp. 1–31, 2021, doi: 10.3390/genes12060835.
10. M. S. P. Dhale, M. L. Fating, A. Bhagat, and S. M. Waghmare, “Case Report on Renal Cell Carcinoma ( Hypernephroma ),” vol. 8, no. 5, pp. 1012–1017, 2021.
11. H. Moch and R. Ohashi, “Chromophobe renal cell carcinoma: current and controversial issues,” Pathology, vol. 53, no. 1, pp. 101–108, 2021, doi: 10.1016/j.pathol.2020.09.015.
12. L. M. Bermejo, B. López-Plaza, C. Santurino, I. Cavero-Redondo, and C. Gómez-Candela, “Milk and Dairy Product Consumption and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Observational Studies,” Adv. Nutr., vol. 10, no. 5, pp. S224–S280, 2019, doi: 10.1093/advances/nmy119.
13. K. J. Wang et al., “Targeting an autocrine regulatory loop in cancer stem-like cells impairs the progression and chemotherapy resistance of bladder cancer,” Clin. Cancer Res., vol. 25, no. 3, pp. 1070–1086, 2019, doi: 10.1158/1078-0432.CCR-18-0586.
14. F. Liu et al., “Dysbiosis signatures of the microbial profile in tissue from bladder cancer,” Cancer Med., vol. 8, no. 16, pp. 6904–6914, 2019, doi: 10.1002/cam4.2419.
15. A. A. Bhat et al., “Tight junction proteins and signaling pathways in cancer and inflammation: A functional crosstalk,” Front. Physiol., vol. 10, no. JAN, pp. 1–19, 2019, doi: 10.3389/fphys.2018.01942.
16. S. A. Tadros et al., “Thymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p,” Int. J. Mol. Sci., vol. 23, no. 24, pp. 1–15, 2022, doi: 10.3390/ijms232415904.
17. E. Yamuç, N. Ö. Barışık, S. Şensu, F. Tarhan, and C. C. Barışık, “Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas,” Indian J. Pathol. Microbiol., vol. 65, no. 2, pp. 355–361, 2022, doi: 10.4103/IJPM.IJPM_914_20.
18. F. Maesaka et al., “Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer,” Int. J. Mol. Sci., vol. 23, no. 12, pp. 1–16, 2022, doi: 10.3390/ijms23126516.
19. P. R. Mohapatra, S. Sahoo, S. Bhuniya, and M. N. Sable, “Endobronchial Metastasis from Resected Renal Cell Carcinoma: An Unusual Presentation After Four Years,” Indian J. Chest Dis. Allied Sci., vol. 62, no. 1, pp. 23–25, 2022, doi: 10.5005/ijcdas-62-1-23.
20. A. M. Rasteiro, E. Sá E Lemos, P. A. Oliveira, and R. M. Gil da Costa, “Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy,” Vet. Sci., vol. 9, no. 3, 2022, doi: 10.3390/vetsci9030107.
21. Y. Zhao et al., “Electrochemical Biosensor Employing Bi2S3 Nanocrystals-Modified Electrode for Bladder Cancer Biomarker Detection,” Chemosensors, vol. 10, no. 2, 2022, doi: 10.3390/chemosensors10020048.
22. M. I. Alshahwan et al., “Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant of Urinary Bladder Cancer With Aggressive Behavior,” Cureus, vol. 15, no. 3, 2023, doi: 10.7759/cureus.36278.
23. M. Alderson, P. Grivas, M. I. Milowsky, and S. E. Wobker, “Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications,” Bl. Cancer, vol. 6, no. 2, pp. 107–122, 2020, doi: 10.3233/BLC-190257.
24. R. AlHalak, S. Alkabbani, H. Nasseif, N. Oghanna, and F. Janahi, “Bladder leiomyoma treated with transurethral resection of bladder tumor (TURBT): Case report,” Int. J. Surg. Case Rep., vol. 98, no. July, p. 107464, 2022, doi: 10.1016/j.ijscr.2022.107464.
25. M. Hamidfar, E. Sheikhpour, M. A. Tafti, F. Daneshmand, and M. Abedinzadeh, “Evaluation of the prognostic value of CD117 and CK20 biomarkers in urinary bladder carcinoma,” Iran. J. Blood Cancer, vol. 14, no. 3, pp. 11–15, 2022, [Online]. Available: www.ijbc.ir
26. Y. Wu et al., “Primary primitive neuroectodermal tumor of urinary bladder: A case report and literature review,” Transl. Cancer Res., vol. 10, no. 11, pp. 4997–5004, 2021, doi: 10.21037/tcr-21-864.
27. T. W. O’Neill and C. V. Löhr, “Mast Cell Tumors and Histiocytomas in Domestic Goats and Diagnostic Utility of CD117/c-Kit and Iba1 Immunohistochemistry,” Vet. Pathol., vol. 58, no. 3, pp. 508–515, 2021, doi: 10.1177/0300985820988145.
28. A. Awadalla, W. I. Mortada, H. Abol-Enein, and A. A. Shokeir, “Correlation between blood levels of cadmium and lead and the expression of microRNA-21 in Egyptian bladder cancer patients,” Heliyon, vol. 6, no. 12, 2020, doi: 10.1016/j.heliyon.2020.e05642.
29. J. Evers, A. J. Grotenhuis, K. K. H. Aben, L. A. L. M. Kiemeney, and A. Vrieling, “No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression,” PLoS One, vol. 15, no. 3, pp. 1–17, 2020, doi: 10.1371/journal.pone.0229384.
30. L. J. Schouten, J. van de Pol, M. J. Kviatkovsky, and P. A. van den Brandt, “Reproductive and external hormonal factors and the risk of renal cell cancer in the Netherlands Cohort Study,” Cancer Epidemiol., vol. 79, no. May, p. 102171, 2022, doi: 10.1016/j.canep.2022.102171.
31. Z. Zhu et al., “Renal Cell Carcinoma Associated With HIV/AIDS: A Review of the Epidemiology, Risk Factors, Diagnosis, and Treatment,” Front. Oncol., vol. 12, no. April, pp. 1–8, 2022, doi: 10.3389/fonc.2022.872438.
32. H. Takeshima and T. Ushijima, “Accumulation of genetic and epigenetic alterations in normal cells and cancer risk,” npj Precis. Oncol., vol. 3, no. 1, pp. 1–8, 2019, doi: 10.1038/s41698-019-0079-0.
33. A. D. Gloor, G. J. Berry, J. J. Goronzy, and C. M. Weyand, “Age as a risk factor in vasculitis,” Semin. Immunopathol., vol. 44, no. 3, pp. 281–301, 2022, doi: 10.1007/s00281-022-00911-1.
34. M. P. Purdue et al., “Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma,” Int. J. Cancer, vol. 149, no. 7, pp. 1448–1454, 2021, doi: 10.1002/ijc.33701.
35. R. Meer, J. van de Pol, P. A. van den Brandt, and L. J. Schouten, “The association of healthy lifestyle index score and the risk of renal cell cancer in the Netherlands cohort study,” BMC Cancer, vol. 23, no. 1, pp. 1–12, 2023, doi: 10.1186/s12885-023-10627-6.
36. C. Il Choi et al., “Comparison by Pentafecta Criteria of Transperitoneal and Retroperitoneal Robotic Partial Nephrectomy for Large Renal Tumors,” J. Endourol., vol. 34, no. 2, pp. 175–183, 2020, doi: 10.1089/end.2019.0410.
37. F. Turco et al., “Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC,” Endocr. Relat. Cancer, vol. 28, no. 7, pp. R207–R216, Jun. 2021, doi: 10.1530/ERC-20-0457.
38. D. Lakens, “Sample Size Justification,” Collabra Psychol., vol. 8, no. 1, pp. 1–28, 2022, doi: 10.1525/collabra.33267.
39. X. He et al., “Eosinophilic solid and cystic renal cell carcinoma with TSC2 mutation: a case report and literature review,” Diagn. Pathol., vol. 18, no. 1, p. 53, 2023, doi: 10.1186/s13000-023-01341-9.
40. D. Grimm et al., “The role of SOX family members in solid tumours and metastasis,” Semin. Cancer Biol., vol. 67, no. March 2019, pp. 122–153, 2020, doi: 10.1016/j.semcancer.2019.03.004.
41. W. Yang et al., “Discovery and validation of the prognostic value of the IncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma,” Aging (Albany. NY)., vol. 12, no. 5, pp. 4424–4444, 2020, doi: 10.18632/aging.102894.
42. S. Safiri et al., “Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease study 2019,” BMJ Glob. Heal., vol. 6, no. 11, pp. 1–15, 2021, doi: 10.1136/bmjgh-2020-004128.
43. Z. Nehme, N. Roehlen, P. Dhawan, and T. F. Baumert, “Tight Junction Protein Signaling and Cancer Biology,” Cells, vol. 12, no. 2, pp. 1–22, 2023, doi: 10.3390/cells12020243.
44. J. Li, “Dysregulated expression of claudins in cancer (Review),” Oncology Letters, vol. 22, no. 3. Spandidos Publications, Sep. 01, 2021. doi: 10.3892/ol.2021.12902.
45. Y. Gong*, Y. Li, X. Ning, X. Li, K. Gong, and L. Zhou, “Mp16-03 Downregulation and Frequent Promoter Hypermethylation of Cldn7 Correlate With Tumor Progression and Poor Prognosis in Human Clear Cell Renal Cell Carcinoma,” J. Urol., vol. 201, no. Supplement 4, p. 2019, 2019, doi: 10.1097/01.ju.0000555339.89148.a4.
46. V. Agarwal et al., “Solitary Metachronous Drop Metastasis of a Rare Variant of Renal Cell Carcinoma to Ipsilateral Ureteric Stump - A Case Report,” Bull. Urooncology, vol. 22, no. 1, pp. 46–49, 2023, doi: 10.4274/uob.galenos.2022.2022.7.1.
47. N. Baniak, H. Tsai, and M. S. Hirsch, “The differential diagnosis of medullary-based renal masses,” Arch. Pathol. Lab. Med., vol. 145, no. 9, pp. 1148–1170, 2021, doi: 10.5858/arpa.2020-0464-RA.
48. Y. A. Prakoso, S. Widyarini, F. C. Faresy, and Y. S. Utomo, “Clinicopathological study of sarcomatoid renal cell carcinoma in animals in East Java, Indonesia, from 2017 to 2022,” Open Vet. J., vol. 13, no. 1, pp. 64–73, 2023, doi: 10.5455/OVJ.2023.v13.i1.7.
49. D. Semjén et al., “Renal cell carcinoma in end-stage renal disease: A retrospective study in patients from Hungary,” Pathobiology, 2023, doi: 10.1159/000529276.
50. M. Farcaş et al., “Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases,” Mod. Pathol., vol. 35, no. 3, pp. 344–351, 2022, doi: 10.1038/s41379-021-00923-6.
51. P. Kapur et al., “Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney,” Mod. Pathol., vol. 35, no. 3, pp. 333–343, 2022, doi: 10.1038/s41379-021-00896-6.
52. S. K. Mohanty et al., “Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway,” Mod. Pathol., vol. 35, no. 3, pp. 361–375, 2022, doi: 10.1038/s41379-021-00969-6.
53. H. Zhang, M. Zhao, Z. Zhang, and D. Cao, “Update on Selected Oncocytic Renal Cell Tumors,” vol. 3, no. 1, pp. 10–19, 2023, doi: 10.14218/JCTP.2022.00032.
2. H. Moch et al., “The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours,” Eur. Urol., vol. 82, no. 5, pp. 458–468, 2022, doi: 10.1016/j.eururo.2022.06.016.
3. V. K. Sarhadi and G. Armengol, “Molecular Biomarkers in Cancer,” Biomolecules, vol. 12, no. 8, pp. 1–39, 2022, doi: 10.3390/biom12081021.
4. I. Lorencin, N. Anđelić, J. Španjol, and Z. Car, “Using multi-layer perceptron with Laplacian edge detector for bladder cancer diagnosis,” Artif. Intell. Med., vol. 102, no. May 2019, 2020, doi: 10.1016/j.artmed.2019.101746.
5. K. L. Ng, “The Etiology of Renal Cell Carcinoma and Upper Tract Urothelial Carcinoma,” Urol. Cancers, pp. 61–69, 2022, doi: 10.36255/exon-publications-urologic-cancers-etiology-renal-cell-carcinoma.
6. H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
7. M. I. Tafwid, A. Rizky, and H. Pratama, “Association between patient with muscle-invasive bladder cancer with the incidence of urinary tract infection in Karawang Regional Hospital : a single center study,” vol. 11, no. 3, pp. 1494–1497, 2022, doi: 10.15562/bmj.v11i3.3823.
8. O. Bratu et al., “Renal tumor biomarkers (Review),” Exp. Ther. Med., vol. 22, no. 5, pp. 1–7, Sep. 2021, doi: 10.3892/etm.2021.10732.
9. A. Cinque, R. Vago, and F. Trevisani, “Circulating rna in kidney cancer: What we know and what we still suppose,” Genes (Basel)., vol. 12, no. 6, pp. 1–31, 2021, doi: 10.3390/genes12060835.
10. M. S. P. Dhale, M. L. Fating, A. Bhagat, and S. M. Waghmare, “Case Report on Renal Cell Carcinoma ( Hypernephroma ),” vol. 8, no. 5, pp. 1012–1017, 2021.
11. H. Moch and R. Ohashi, “Chromophobe renal cell carcinoma: current and controversial issues,” Pathology, vol. 53, no. 1, pp. 101–108, 2021, doi: 10.1016/j.pathol.2020.09.015.
12. L. M. Bermejo, B. López-Plaza, C. Santurino, I. Cavero-Redondo, and C. Gómez-Candela, “Milk and Dairy Product Consumption and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Observational Studies,” Adv. Nutr., vol. 10, no. 5, pp. S224–S280, 2019, doi: 10.1093/advances/nmy119.
13. K. J. Wang et al., “Targeting an autocrine regulatory loop in cancer stem-like cells impairs the progression and chemotherapy resistance of bladder cancer,” Clin. Cancer Res., vol. 25, no. 3, pp. 1070–1086, 2019, doi: 10.1158/1078-0432.CCR-18-0586.
14. F. Liu et al., “Dysbiosis signatures of the microbial profile in tissue from bladder cancer,” Cancer Med., vol. 8, no. 16, pp. 6904–6914, 2019, doi: 10.1002/cam4.2419.
15. A. A. Bhat et al., “Tight junction proteins and signaling pathways in cancer and inflammation: A functional crosstalk,” Front. Physiol., vol. 10, no. JAN, pp. 1–19, 2019, doi: 10.3389/fphys.2018.01942.
16. S. A. Tadros et al., “Thymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p,” Int. J. Mol. Sci., vol. 23, no. 24, pp. 1–15, 2022, doi: 10.3390/ijms232415904.
17. E. Yamuç, N. Ö. Barışık, S. Şensu, F. Tarhan, and C. C. Barışık, “Correlation of REG1A, Claudin 7 and Ki67 expressions with tumor recurrence and prognostic factors in superficial urothelial urinary bladder carcinomas,” Indian J. Pathol. Microbiol., vol. 65, no. 2, pp. 355–361, 2022, doi: 10.4103/IJPM.IJPM_914_20.
18. F. Maesaka et al., “Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer,” Int. J. Mol. Sci., vol. 23, no. 12, pp. 1–16, 2022, doi: 10.3390/ijms23126516.
19. P. R. Mohapatra, S. Sahoo, S. Bhuniya, and M. N. Sable, “Endobronchial Metastasis from Resected Renal Cell Carcinoma: An Unusual Presentation After Four Years,” Indian J. Chest Dis. Allied Sci., vol. 62, no. 1, pp. 23–25, 2022, doi: 10.5005/ijcdas-62-1-23.
20. A. M. Rasteiro, E. Sá E Lemos, P. A. Oliveira, and R. M. Gil da Costa, “Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy,” Vet. Sci., vol. 9, no. 3, 2022, doi: 10.3390/vetsci9030107.
21. Y. Zhao et al., “Electrochemical Biosensor Employing Bi2S3 Nanocrystals-Modified Electrode for Bladder Cancer Biomarker Detection,” Chemosensors, vol. 10, no. 2, 2022, doi: 10.3390/chemosensors10020048.
22. M. I. Alshahwan et al., “Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant of Urinary Bladder Cancer With Aggressive Behavior,” Cureus, vol. 15, no. 3, 2023, doi: 10.7759/cureus.36278.
23. M. Alderson, P. Grivas, M. I. Milowsky, and S. E. Wobker, “Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications,” Bl. Cancer, vol. 6, no. 2, pp. 107–122, 2020, doi: 10.3233/BLC-190257.
24. R. AlHalak, S. Alkabbani, H. Nasseif, N. Oghanna, and F. Janahi, “Bladder leiomyoma treated with transurethral resection of bladder tumor (TURBT): Case report,” Int. J. Surg. Case Rep., vol. 98, no. July, p. 107464, 2022, doi: 10.1016/j.ijscr.2022.107464.
25. M. Hamidfar, E. Sheikhpour, M. A. Tafti, F. Daneshmand, and M. Abedinzadeh, “Evaluation of the prognostic value of CD117 and CK20 biomarkers in urinary bladder carcinoma,” Iran. J. Blood Cancer, vol. 14, no. 3, pp. 11–15, 2022, [Online]. Available: www.ijbc.ir
26. Y. Wu et al., “Primary primitive neuroectodermal tumor of urinary bladder: A case report and literature review,” Transl. Cancer Res., vol. 10, no. 11, pp. 4997–5004, 2021, doi: 10.21037/tcr-21-864.
27. T. W. O’Neill and C. V. Löhr, “Mast Cell Tumors and Histiocytomas in Domestic Goats and Diagnostic Utility of CD117/c-Kit and Iba1 Immunohistochemistry,” Vet. Pathol., vol. 58, no. 3, pp. 508–515, 2021, doi: 10.1177/0300985820988145.
28. A. Awadalla, W. I. Mortada, H. Abol-Enein, and A. A. Shokeir, “Correlation between blood levels of cadmium and lead and the expression of microRNA-21 in Egyptian bladder cancer patients,” Heliyon, vol. 6, no. 12, 2020, doi: 10.1016/j.heliyon.2020.e05642.
29. J. Evers, A. J. Grotenhuis, K. K. H. Aben, L. A. L. M. Kiemeney, and A. Vrieling, “No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression,” PLoS One, vol. 15, no. 3, pp. 1–17, 2020, doi: 10.1371/journal.pone.0229384.
30. L. J. Schouten, J. van de Pol, M. J. Kviatkovsky, and P. A. van den Brandt, “Reproductive and external hormonal factors and the risk of renal cell cancer in the Netherlands Cohort Study,” Cancer Epidemiol., vol. 79, no. May, p. 102171, 2022, doi: 10.1016/j.canep.2022.102171.
31. Z. Zhu et al., “Renal Cell Carcinoma Associated With HIV/AIDS: A Review of the Epidemiology, Risk Factors, Diagnosis, and Treatment,” Front. Oncol., vol. 12, no. April, pp. 1–8, 2022, doi: 10.3389/fonc.2022.872438.
32. H. Takeshima and T. Ushijima, “Accumulation of genetic and epigenetic alterations in normal cells and cancer risk,” npj Precis. Oncol., vol. 3, no. 1, pp. 1–8, 2019, doi: 10.1038/s41698-019-0079-0.
33. A. D. Gloor, G. J. Berry, J. J. Goronzy, and C. M. Weyand, “Age as a risk factor in vasculitis,” Semin. Immunopathol., vol. 44, no. 3, pp. 281–301, 2022, doi: 10.1007/s00281-022-00911-1.
34. M. P. Purdue et al., “Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma,” Int. J. Cancer, vol. 149, no. 7, pp. 1448–1454, 2021, doi: 10.1002/ijc.33701.
35. R. Meer, J. van de Pol, P. A. van den Brandt, and L. J. Schouten, “The association of healthy lifestyle index score and the risk of renal cell cancer in the Netherlands cohort study,” BMC Cancer, vol. 23, no. 1, pp. 1–12, 2023, doi: 10.1186/s12885-023-10627-6.
36. C. Il Choi et al., “Comparison by Pentafecta Criteria of Transperitoneal and Retroperitoneal Robotic Partial Nephrectomy for Large Renal Tumors,” J. Endourol., vol. 34, no. 2, pp. 175–183, 2020, doi: 10.1089/end.2019.0410.
37. F. Turco et al., “Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC,” Endocr. Relat. Cancer, vol. 28, no. 7, pp. R207–R216, Jun. 2021, doi: 10.1530/ERC-20-0457.
38. D. Lakens, “Sample Size Justification,” Collabra Psychol., vol. 8, no. 1, pp. 1–28, 2022, doi: 10.1525/collabra.33267.
39. X. He et al., “Eosinophilic solid and cystic renal cell carcinoma with TSC2 mutation: a case report and literature review,” Diagn. Pathol., vol. 18, no. 1, p. 53, 2023, doi: 10.1186/s13000-023-01341-9.
40. D. Grimm et al., “The role of SOX family members in solid tumours and metastasis,” Semin. Cancer Biol., vol. 67, no. March 2019, pp. 122–153, 2020, doi: 10.1016/j.semcancer.2019.03.004.
41. W. Yang et al., “Discovery and validation of the prognostic value of the IncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma,” Aging (Albany. NY)., vol. 12, no. 5, pp. 4424–4444, 2020, doi: 10.18632/aging.102894.
42. S. Safiri et al., “Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease study 2019,” BMJ Glob. Heal., vol. 6, no. 11, pp. 1–15, 2021, doi: 10.1136/bmjgh-2020-004128.
43. Z. Nehme, N. Roehlen, P. Dhawan, and T. F. Baumert, “Tight Junction Protein Signaling and Cancer Biology,” Cells, vol. 12, no. 2, pp. 1–22, 2023, doi: 10.3390/cells12020243.
44. J. Li, “Dysregulated expression of claudins in cancer (Review),” Oncology Letters, vol. 22, no. 3. Spandidos Publications, Sep. 01, 2021. doi: 10.3892/ol.2021.12902.
45. Y. Gong*, Y. Li, X. Ning, X. Li, K. Gong, and L. Zhou, “Mp16-03 Downregulation and Frequent Promoter Hypermethylation of Cldn7 Correlate With Tumor Progression and Poor Prognosis in Human Clear Cell Renal Cell Carcinoma,” J. Urol., vol. 201, no. Supplement 4, p. 2019, 2019, doi: 10.1097/01.ju.0000555339.89148.a4.
46. V. Agarwal et al., “Solitary Metachronous Drop Metastasis of a Rare Variant of Renal Cell Carcinoma to Ipsilateral Ureteric Stump - A Case Report,” Bull. Urooncology, vol. 22, no. 1, pp. 46–49, 2023, doi: 10.4274/uob.galenos.2022.2022.7.1.
47. N. Baniak, H. Tsai, and M. S. Hirsch, “The differential diagnosis of medullary-based renal masses,” Arch. Pathol. Lab. Med., vol. 145, no. 9, pp. 1148–1170, 2021, doi: 10.5858/arpa.2020-0464-RA.
48. Y. A. Prakoso, S. Widyarini, F. C. Faresy, and Y. S. Utomo, “Clinicopathological study of sarcomatoid renal cell carcinoma in animals in East Java, Indonesia, from 2017 to 2022,” Open Vet. J., vol. 13, no. 1, pp. 64–73, 2023, doi: 10.5455/OVJ.2023.v13.i1.7.
49. D. Semjén et al., “Renal cell carcinoma in end-stage renal disease: A retrospective study in patients from Hungary,” Pathobiology, 2023, doi: 10.1159/000529276.
50. M. Farcaş et al., “Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases,” Mod. Pathol., vol. 35, no. 3, pp. 344–351, 2022, doi: 10.1038/s41379-021-00923-6.
51. P. Kapur et al., “Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney,” Mod. Pathol., vol. 35, no. 3, pp. 333–343, 2022, doi: 10.1038/s41379-021-00896-6.
52. S. K. Mohanty et al., “Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway,” Mod. Pathol., vol. 35, no. 3, pp. 361–375, 2022, doi: 10.1038/s41379-021-00969-6.
53. H. Zhang, M. Zhao, Z. Zhang, and D. Cao, “Update on Selected Oncocytic Renal Cell Tumors,” vol. 3, no. 1, pp. 10–19, 2023, doi: 10.14218/JCTP.2022.00032.
Published
2023-09-27
How to Cite
Hatem, A. K., & Jasim, F. A. (2023). Clinical Significance of Some Biomarkers in the Detection of Kidney and Bladder Cancers. Central Asian Journal of Medical and Natural Science, 4(5), 305-315. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1820
Section
Articles
